Synaptic markers - synaptophysin and PSD-95 -were also statistically significantly reduced, by 14 and 29%, respectively.GK-2 in both administration schedules completely restored the level of Ki67immunoreactivity in the hippocampus and promoted its increase in the striatum.In addition, GK-2 restored the level of the postsynaptic marker PSD-95, withthe therapeutic effect amounting to 70% at the start of its administrationafter 6 h, and promoted restoration of the level of this marker at the start ofadministration 24 h after an experimental stroke. The gene discussed is DLG4; the disease is Stroke.